In the past few years pharmaceutical companies have developed a string of new Alzheimer’s drugs called anti-amyloids, which target amyloid plaques in patients’ brains. These plaques are one of the key biomarkers of the disease.
The first of these drugs, Aduhelm, was approved by the FDA in 2021 amid enormous controversy. The FDA approved the drug despite little evidence that it actually slowed cognitive decline in patients. Biogen, the maker of Aduhelm, pulled the plug on further research or sales of the drug last month.
In January 2023 The FDA approved another anti-amyloid medication from Biogen, lecanemab, sold under the brand name Leqembi. This time, there was much stronger evidence. Clinical trial results showed that the drug showed a modest improvement in cognitive decline in the early phases of the disease. But the drug comes with risks, including brain swelling and bleeding.
Most recently, at the beginning of March, the FDA delayed approval of another anti-amyloid drug, donanemab, created by Eli Lilly. The FDA said it will be conducting an additional review to further scrutinize the study design and efficacy data.
From the outside looking in, these Alzheimer’s drugs appear to be mired in controversy. How well do they actually work? And why has there been so much back and forth with the FDA?
To answer those questions and more, guest host Arielle Duhaime-Ross talks with Dr. Jason Karlawish, professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine, and co-director of the Penn Memory Center.
Transcripts for each segment will be available after the show airs on sciencefriday.com.
Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.
637: How Poisons Have Shaped Life On Earth
635: Placenta Research May Help Explain Pregnancy Loss
634: A Common Cold Medicine Ingredient Doesn’t Work. What Now?
633: Diving Into Elon Musk’s Mind
636: RSV Drug Shortage & Beech Leaf Disease
632: When Studying Ecology Means Celebrating Its Gifts
632: Unlocking The Mysteries Of A Metal-Rich Asteroid
631: Rapidly Evolving Trout & Ancient Hyper-Apex Predators
630: Finding Meaning In The Cosmos
630: ‘Clean Hydrogen Hub’ Awardees & Formula One Car Paint
628: What Is Your Cat Doing When You're Not Watching?
629: The Stories Of The First Six Women Astronauts
627: A Mathematician Asks ‘Is Math Real?’
628: The mRNA Vaccine Revolution
626: Ancient Human Footprints & 'Ring Of Fire' Eclipse
623: Saltwater Wedge In The Mississippi & Kenya's Geothermal Boom
625: How Artists And Scientists Collaborated To Make Art About HIV
622: Full-Body MRIs Promise To Detect Disease Early. Do They Work?
623: Meet The Doctor Who Solves Medical Mysteries
624: mRNA Research Wins Nobel Prize & Lightning On Venus
Create your
podcast in
minutes
It is Free
The Modern West
Voices of Misery Podcast
House of Whimsical Terror
Dairyland Frights
Stuff You Should Know
Timcast IRL